MétaCan
Menu
Back to cohort
Record W2016088001 · doi:10.5430/jst.v2n6p4

Oral vinorelbine: a Better Choice for Concurrent Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer

2012· article· en· W2016088001 on OpenAlexvenueno aff
Wei-Hsin Chiu, H.H. Chen, Wu‐Chou Su

Bibliographic record

VenueJournal of Solid Tumors · 2012
Typearticle
Languageen
FieldMedicine
TopicLung Cancer Diagnosis and Treatment
Canadian institutionsnot available
Fundersnot available
KeywordsVinorelbineMedicineLung cancerChemoradiotherapyClinical endpointPneumonitisInternal medicineRadiation therapyStage (stratigraphy)SurgeryOncologyChemotherapyLungRandomized controlled trial

Abstract

fetched live from OpenAlex

Background: Lung cancer is the most common cancer in the world, and causes 1.3 million deaths annually. Approximately 45% of patients diagnosed with non-small cell lung cancer (NSCLC) have locally advanced stage III disease. Standard treatment is concurrent chemoradiotherapy (CCRT) with two drugs, but severe toxicities are common. Several single-agent CCRTs have been developed to overcome this problem. Methods: We reviewed the records of 24 patients with stage III NSCLC who received single-agent vinorelbine CCRT at the National Cheng Kung University Hospital from January 1, 2005 to May 31, 2009. Nine patients received with vinorelbine intravenous infusion (15 mg/m 2 /week) and fifteen with oral vinorelbine 40mg/m 2 /week. Thoracic radiation was given over 6 weeks in 1.8 Gy/day fractions (total median dose of 59.7 Gy). The primary endpoint was the evaluation of time to progression (TTP) of these patients. The secondary endpoints were analysis of therapy-related toxicities and overall response rate. Results: Median age was 70 years (range: 58-81 years), and median follow-up time was 430 days (range: 101-1363 days). Eighteen patients were male, six were female and the median ECOG grade was 1. Vinorelbine was given for a median of 5.5 weeks (range: 4-8 weeks). All patients completed all planned cycles of CCRT. Seven patients (29.2%) had radiation pneumonitis. No patient had a complete response, and thirteen patients (54.2%) had a partial response. The median time to progression (TTP) was 6.4 months (95% confidence interval: 4-8.7 months), the median survival time was 24 months (95% CI: 13.8-34.9 months), and the 1- and 2-year survival rates were 68.5% and 41.1%, respectively. Conclusion: Treatment of stage III NSCLC patients with single-agent vinorelbine CCRT had a better median survival time and 2-year survival rates with fewer toxicities when compared with other therapies. Oral vinorelbine with its convenience in administration is an ideal choice for CCRT.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.178
Threshold uncertainty score0.589

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.019
GPT teacher head0.339
Teacher spread0.320 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations4
Published2012
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Solid TumorsSame topicLung Cancer Diagnosis and TreatmentFrench-language works237,207